ランダム化臨床試験における非がん関連死亡率:メタ解析
Jiayao Lei1,2,3, Yunyang Deng1, Mark Clements1
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
JAMA network open
|August 25, 2025
まとめ
癌のスクリーニングは非癌の死亡率を 大きく増加させません 標的と非標的の死亡率を別々に評価することは,スクリーニングの影響を完全に理解するために不可欠です.
科学分野:
- 腫瘍学
- 公衆衛生
- バイオ統計学
背景:
- 癌の検診は癌の死亡率を減らすために不可欠ですが,過剰診断などのリスクがあります.
- すべての原因による死亡率だけでスクリーニングの影響を評価することは,利益と害に対して無感性であるため不十分です.
- 非がん関連 (非標的) 死亡率を理解することは,がんスクリーニングの包括的な評価に不可欠です.
研究 の 目的:
- 癌のスクリーニングと非目標死亡率の関連性を評価する.
- ランダム化臨床試験 (RCT) を用いて,スクリーニングとスクリーニングされていない個人の死亡率を比較する.
主な方法:
- 癌のスクリーニングに関する既存のRCTの体系的なレビューとメタ分析.
- すべての原因と標的がんの死亡率に関するデータを含むRCT.
- 率比 (RRs) と95%信頼区間 (CI) を用いて固定効果モデルを用いて,対象外死亡率を分析した.
主要な成果:
- 130万人以上の参加者を対象とした17件のRCTの分析
- 癌のスクリーニングでは,標的外死亡率の有意な増加は見られなかった (RR,1. 00; 95% CI,1. 00-1. 01).
- 標的外死亡率の全体的な増加は最小値 (0. 2%) であり,有意な異質性は観察されなかった.
結論:
- 癌のスクリーニングは,非癌による死亡率の大幅な増加と関連していません.
- 標的と非標的の死亡率を独立に分析する重要性を強調しています.
- あらゆる原因による死亡率に 頼るだけで がん検診の本当の効果は 隠されるかもしれません
関連する概念動画
Hazard Ratio
243
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
243
Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
Clinical Trials
8.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Comparing the Survival Analysis of Two or More Groups
285
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
285


